Please select the option that best describes you:
Would you use neoadjuvant CDK4/6 inhibitor and AI in HR+ breast cancer based upon the randomized phase II CORALLEEN trial?
Answer from: Medical Oncologist at Academic Institution
I would not use CDK inhibitors in the neoadjuvant setting.
Sign in or Register to read more